Is correction for age necessary in neuroimaging studies of the central serotonin transporter?

The central neurotransmitter serotonin plays a major role in a number of neuropsychiatric disorders. However, results from post-mortem and in vivo neuroimaging studies of the influence of age on the number of presynaptic serotonin transporters (SERT) are controversial. To provide further evidence of relevance for this ongoing discussion, SERT were imaged in 22 persons without neuropsychiatric impairment using [123I]2β-carbomethoxy-3β-(iodophenyl)tropane ([123I]β-CIT) and high-resolution single-photon emission tomography (SPET). The SPET analysis method was based on magnetic resonance image co-registration in order to quantify SERT with acceptable inter- and intra-observer variability. Using this technique, we found a significant age-related decline in the thalamic/hypothalamic and midbrain/upper brainstem SERT density, which was more pronounced than that previously reported in the literature. From these results we conclude that age-related changes in SERT density need to be considered in future clinical studies.

[1]  D. Kupfer,et al.  Serotonin in Aging, Late-Life Depression, and Alzheimer's Disease: The Emerging Role of Functional Imaging , 1998, Neuropsychopharmacology.

[2]  J. Seibyl,et al.  Age-related decline in central serotonin transporter availability with [(123)I]beta-CIT SPECT. , 2000, Neurobiology of aging.

[3]  I. Moilanen,et al.  Elevated hypothalamic/midbrain serotonin (monoamine) transporter availability in depressive drug-naive children and adolescents , 2000, Molecular Psychiatry.

[4]  J. Marcusson,et al.  Effect of aging in human cortical pre- and postsynaptic serotonin binding sites , 1993, Brain Research.

[5]  T. Wächter,et al.  Striatal [123I]β-CIT SPECT and prefrontal cognitive functions in Parkinson's disease , 2000, Journal of Neural Transmission.

[6]  M. Fujita,et al.  Assessment of affinities of beta-CIT, beta-CIT-FE, and beta-CIT-FP for monoamine transporters permanently expressed in cell lines. , 1998, Nuclear medicine and biology.

[7]  M. Torrens.  Co-Planar Stereotaxic Atlas of the Human Brain—3-Dimensional Proportional System: An Approach to Cerebral Imaging, J. Talairach, P. Tournoux. Georg Thieme Verlag, New York (1988), 122 pp., 130 figs. DM 268 , 1990 .

[8]  H. Barthel,et al.  Differential alteration of the nigrostriatal dopaminergic system in Wilson's disease investigated with [123I]ß-CIT and high-resolution SPET , 2001, European Journal of Nuclear Medicine.

[9]  J. Tiihonen,et al.  Effects of ageing on serotonin transporters in healthy females , 2001, European Journal of Nuclear Medicine.

[10]  B. Olivier,et al.  Serotonin, dopamine and norepinephrine transporters in the central nervous system and their inhibitors. , 2000, Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques.

[11]  Shitij Kapur,et al.  Serotonin 5-HT1A Receptor Binding Potential Declines with Age as Measured by [11C]WAY-100635 and PET , 2001, Neuropsychopharmacology.

[12]  J. Seibyl,et al.  Age-related decline in central serotonin transporter availability with [123I]β-CIT SPECT , 2000, Neurobiology of Aging.

[13]  J Tauscher,et al.  Imaging serotonin and dopamine transporters with 123I-beta-CIT SPECT: binding kinetics and effects of normal aging. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[14]  M Fujita,et al.  Sex differences in [123I]β‐CIT SPECT measures of dopamine and serotonin transporter availability in healthy smokers and nonsmokers , 2001, Synapse.

[15]  D. V. von Cramon,et al.  In vivo evidence for differential association of striatal dopamine and midbrain serotonin systems with neuropsychiatric symptoms in Parkinson's disease. , 2001, The Journal of neuropsychiatry and clinical neurosciences.

[16]  J. Marcusson,et al.  Age stability of human brain 5-HT terminals studied with [3H]paroxetine binding. , 1992, Gerontology.